Ezra, a NY-based startup focused on early cancer screening using MRI and artificial intelligence, raised $18M in funding.
The round was led by FirstMark Capital, with participation from new investors Jeff Raider and Dave Gilboa (co-founders of Harry’s and Warby Parker), Vlad Tenev (co-founder of Robinhood), Fred Destin (co-founder of Stride VC), and Andrei Dunca (co-founder & CTO of LiveRail) and existing investors Accomplice, Seedcamp, Credo Ventures, Founders Future, LDV Capital, Esther Dyson, Taavet Hinrikus, Daniel Dines, Dave McClure, and Jeremy Arditi also participated. Rick Heitzmann, partner and founder of FirstMark Capital. Mr. Heitzmann will join the Ezra board of directors alongside Mr. Gal, Diego Cantor PhD, Ezra’s CTO and co-founder, and existing investor Ryan Moore, partner at Accomplice.
The company intends to use the funds to expand its medical imaging AIs to make MRI-based cancer screening more accessible and roll out Ezra COVID 360, a low-dose CT scan of the lungs to look for damage caused by COVID-19, paired with an antibody blood test to check for igG and igM antibodies. The new plan is designed for individuals who want to understand the potential long-term impact of COVID-19 on their lung health and check their antibody status. Ezra COVID 360 will be available for $390 in New York City starting June 1st, and the company is working on expanding the plan across California in the upcoming weeks. Ezra will offer 50 free plans to medical providers and first responders who have been on the frontlines of COVID-19.
Led by Emi Gal, CEO and co-founder, Ezra launched its MRI-based prostate cancer screening program in January 2019, and rolled out its full-body MRI scan in May 2019. The company partners with existing outpatient imaging facilities, and all Ezra scans are analyzed by board-certified radiologists. The company’s cancer screening programs are live in New York City, San Francisco, and Los Angeles through its partnership with RadNet, Inc., a leader in outpatient imaging. Ezra has R&D operations in Toronto.